Test systems in Drug Discovery for hazard identification and risk assessment of human Drug-Induced Liver Injury

Autor: Weaver, RJ, Betts, C, Blomme, EAG, Gerets, HHJ, Gjervig Jensen, K, Hewitt, PG, Juhila, S, Labbe, G, Liguori, MJ, Mesens, N, Ogese, MO, Persson, M, Snoeys, J, Stevens, JL, Walker, T, Park, BK

Publikováno v: Expert opinion on drug metabolism & toxicology

Introduction The liver is an important target for drug-induced toxicities. Early detection of hepatotoxic drugs requires use of well-characterized test systems, yet current knowledge, gaps and limitations of tests employed remains an important issue

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::37f47d10edd3d3971facceffb220ca8f

Small Molecule Induces Time-Dependent Inhibition of Stat3 Dimerization and DNA-Binding Activity and Regresses Human Breast Tumor Xenografts.

Autor: Yue P; Department of Medicine, Division of Hematology-Oncology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Davis 5065, Los Angeles, CA, 90048, USA.; Cancer Biology Program, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA., Chen Y; Department of Medicine, Division of Hematology-Oncology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Davis 5065, Los Angeles, CA, 90048, USA.; Cancer Biology Program, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.; Department of Basic Medicine, Suzhou Vocational Health College, Suzhou, 215009, China., Ogese MO; Department of Medicine, Division of Hematology-Oncology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Davis 5065, Los Angeles, CA, 90048, USA.; Cancer Biology Program, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA., Sun S; Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, 847 Monroe Avenue, Suite 327, Memphis, TN, 38163, USA., Zhang X; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical, Sciences, Sun Yat-Sen University, Guangzhou, 510006, China., Esan T; Department of Pharmaceutical Sciences, College of Pharmacy, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL, 60064-3095, USA., Buolamwini JK; Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, 847 Monroe Avenue, Suite 327, Memphis, TN, 38163, USA.; Department of Pharmaceutical Sciences, College of Pharmacy, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL, 60064-3095, USA., Turkson J; Department of Medicine, Division of Hematology-Oncology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Davis 5065, Los Angeles, CA, 90048, USA.; Cancer Biology Program, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.

Publikováno v: Chembiochem : a European journal of chemical biology [Chembiochem] 2024 Aug 21, pp. e202400351. Date of Electronic Publication: 2024 Aug 21.

Loss-of-function mutations in Keratin 32 gene disrupt skin immune homeostasis in pityriasis rubra pilaris.

Autor: Shi P; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Chen W; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Lyu X; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Wang Z; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Li W; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Jia F; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Zheng C; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Liu T; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Wang C; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Zhang Y; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Mi Z; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Sun Y; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Chen X; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Chen S; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Zhou G; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Liu Y; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Lin Y; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Bai F; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China., Sun Q; Department of Dermatology, Qilu Hospital, Shandong University, Jinan, Shandong, China., Ogese MO; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK., Yu Q; Genome Institute of Singapore, Singapore, Singapore., Liu J; Genome Institute of Singapore, Singapore, Singapore., Liu H; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China. hongyue2519@hotmail.com.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China. hongyue2519@hotmail.com.; School of Public Health, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. hongyue2519@hotmail.com., Zhang F; Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China. zhangfuren@hotmail.com.; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China. zhangfuren@hotmail.com.; School of Public Health, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. zhangfuren@hotmail.com.; Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. zhangfuren@hotmail.com.

Publikováno v: Nature communications [Nat Commun] 2024 Jul 24; Vol. 15 (1), pp. 6259. Date of Electronic Publication: 2024 Jul 24.

A blinded in vitro analysis of the intrinsic immunogenicity of hepatotoxic drugs: implications for preclinical risk assessment.

Autor: Ogese MO; Department of Pharmacology and Therapeutic, MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L693GE, UK.; Development Science, UCB Biopharma, Slough, Berkshire SL1 3WE, UK., Lister A; Department of Pharmacology and Therapeutic, MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L693GE, UK., Farrell L; Department of Pharmacology and Therapeutic, MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L693GE, UK., Gardner J; Department of Pharmacology and Therapeutic, MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L693GE, UK., Kafu L; Department of Pharmacology and Therapeutic, MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L693GE, UK., Ali SE; Department of Pharmacology and Therapeutic, MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L693GE, UK., Gibson A; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia., Hillegas A; Immunological Toxicology, In Vitro/In Vivo Translation, GSK, Collegeville, Pennsylvania, USA., Meng X; Department of Pharmacology and Therapeutic, MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L693GE, UK., Pirmohamed M; Department of Pharmacology and Therapeutic, MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L693GE, UK., Williams GS; Immunological Toxicology, In Vitro/In Vivo Translation, GSK, David Jack Centre for R&D, Ware, Hertfordshire SG12 0DP, UK., Sakatis MZ; Global Investigative Safety, In Vitro/In Vivo Translation, GSK, David Jack Centre for R&D, Ware, Hertfordshire SG12 0DP, UK., Naisbitt DJ; Department of Pharmacology and Therapeutic, MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L693GE, UK.

Publikováno v: Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2023 Dec 21; Vol. 197 (1), pp. 38-52.

HLA Class-II‒Restricted CD8 ⁺ T Cells Contribute to the Promiscuous Immune Response in Dapsone-Hypersensitive Patients.

Autor: Zhao Q; MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool, Liverpool, United Kingdom; Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China., Almutairi M; MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool, Liverpool, United Kingdom., Tailor A; MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool, Liverpool, United Kingdom., Lister A; MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool, Liverpool, United Kingdom., Harper N; MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool, Liverpool, United Kingdom., Line J; MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool, Liverpool, United Kingdom., Meng X; MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool, Liverpool, United Kingdom., Pratoomwun J; Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Centre (SDMC), Ramathibodi Hospital, Bangkok, Thailand; Faculty of Medical Technology, Huachiew Chalermprakiet University, Samut Prakan, Thailand., Jaruthamsophon K; MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool, Liverpool, United Kingdom; Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., Sukasem C; Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Centre (SDMC), Ramathibodi Hospital, Bangkok, Thailand., Sun Y; Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China., Sun L; Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China., Ogese MO; MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool, Liverpool, United Kingdom., MacEwan DJ; MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool, Liverpool, United Kingdom., Pirmohamed M; MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool, Liverpool, United Kingdom., Liu J; Human Genetics, Genome Institute of Singapore, A∗STAR, Singapore., Ostrov DA; Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA., Liu H; Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China., Zhang F; Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China. Electronic address: zhangfuren@hotmail.com., Naisbitt DJ; MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool, Liverpool, United Kingdom.

Publikováno v: The Journal of investigative dermatology [J Invest Dermatol] 2021 Oct; Vol. 141 (10), pp. 2412-2425.e2. Date of Electronic Publication: 2021 Mar 30.